NJHF awards $135K to Kessler Foundation scientists for pilot research projects

This year, New Jersey Health Foundation (NJHF) granted $135,000 in awards to three Kessler Foundation scientists to support pilot research projects that exhibit promising potential.

Controversial Alzheimer’s Drug Abandoned

Biogen will discontinue its controversial Alzheimer’s disease drug aducanumab (Aduhelm), the company announced Wednesday. The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal

February 1, 2024

Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality

LOUISVILLE, Ky. — Large tumor size and high disease grade were associated with an increased risk of early cancer-related death in patients with high-risk, non-metastatic

November 13, 2024

Study finds long-term cognitive and psychiatric issues persist in COVID-19 patients two to three years post-infection

A recent study investigated whether psychiatric and cognitive symptoms commence or persist beyond a year of COVID-19-related hospitalization.

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.